Cargando…

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

BACKGROUND: There is an increasing interest for Notch signalling pathway and particularly Delta-like ligand 4 (DLL4) as potential therapeutic target to improve outcome for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Using immunohistochemistry (IHC) and tissue microarray (TMA), we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104892/ https://www.ncbi.nlm.nih.gov/pubmed/27755532 http://dx.doi.org/10.1038/bjc.2016.319

Ejemplares similares

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2009)

Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
por: Jubb, A M, et al.
Publicado: (2009)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer
por: Verset, L, et al.
Publicado: (2013)

Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
por: Smith, R A, et al.
Publicado: (2011)

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
por: Bafna, S, et al.
Publicado: (2009)

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
por: Ferdinande, L, et al.
Publicado: (2012)

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
por: Maftouh, M, et al.
Publicado: (2014)

Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells: What Do We Know So Far?
por: Demetter, Pieter, et al.
Publicado: (2021)

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
por: Mitsunaga, S, et al.
Publicado: (2013)

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma
por: Xue, A, et al.
Publicado: (2012)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2010)

Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients
por: Tonini, G, et al.
Publicado: (2005)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
por: Hadano, Naoto, et al.
Publicado: (2016)

Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer
por: van der Zee, J A, et al.
Publicado: (2012)

hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma
por: Lastraioli, E, et al.
Publicado: (2015)

Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia
por: Moniaux, N, et al.
Publicado: (2008)

UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas
por: Pallante, P, et al.
Publicado: (2005)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

Poly(A) RT–PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer
por: Oliveira-Cunha, M, et al.
Publicado: (2011)

Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling
por: Atrih, A, et al.
Publicado: (2014)

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis
por: De Smedt, L, et al.
Publicado: (2015)

Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation
por: Hiraoka, N, et al.
Publicado: (2010)

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma
por: McCormick Matthews, L H, et al.
Publicado: (2015)

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
por: Kahlert, C, et al.
Publicado: (2009)

Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection
por: Hu, P, et al.
Publicado: (2013)

Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary
por: Bridgewater, J, et al.
Publicado: (2008)

Treatment of Pancreatic Cancer: What Can We Really Predict Today?
por: Bachet, Jean-Baptiste, et al.
Publicado: (2011)

S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility
por: Nedjadi, T, et al.
Publicado: (2009)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Prognostic value of peritumoral heat-shock factor-1 in patients receiving resection of hepatocellular carcinoma
por: Zhang, J-B, et al.
Publicado: (2013)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
por: Irlam-Jones, J J, et al.
Publicado: (2016)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ov2o1tdbrsrssuu21ns4jtfce3